Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Earnings for Amylyx Pharmaceuticals, Inc. (AMLX)
Earnings in 2023 (TTM): $54.3 M
According to Amylyx Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $54.3 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Amylyx Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $54.3 M | $49.27 M |
| 2022 | $-197,601,000 | $-198,375,000 |
| 2021 | $-87,931,000 | $-87,879,000 |
| 2020 | $-42,280,000 | $-44,837,000 |
| 2019 | $-13,716,000 | $-14,816,000 |